- Home
- GKOS vs BKU Comparison
GKOS vs BKU Comparison
Compare GKOS & BKU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- BKU
- Stock Information
- Founded
- GKOS 1998
- BKU 2009
- Country
- GKOS United States
- BKU United States
- Employees
- GKOS N/A
- BKU N/A
- Industry
- GKOS Medical/Dental Instruments
- BKU Savings Institutions
- Sector
- GKOS Health Care
- BKU Finance
- Exchange
- GKOS Nasdaq
- BKU Nasdaq
- Market Cap
- GKOS 5.1B
- BKU N/A
- IPO Year
- GKOS 2015
- BKU 2011
- Fundamental
- Price
- GKOS $89.73
- BKU $31.87
- Analyst Decision
- GKOS Strong Buy
- BKU Hold
- Analyst Count
- GKOS 13
- BKU 11
- Target Price
- GKOS $155.00
- BKU $41.55
- AVG Volume (30 Days)
- GKOS 981.4K
- BKU 922.3K
- Earning Date
- GKOS 04-30-2025
- BKU 04-28-2025
- Dividend Yield
- GKOS N/A
- BKU 3.92%
- EPS Growth
- GKOS N/A
- BKU 29.58
- EPS
- GKOS N/A
- BKU 3.08
- Revenue
- GKOS $383,481,000.00
- BKU $958,349,000.00
- Revenue This Year
- GKOS $27.84
- BKU $16.14
- Revenue Next Year
- GKOS $27.99
- BKU $7.01
- P/E Ratio
- GKOS N/A
- BKU $10.25
- Revenue Growth
- GKOS 21.85
- BKU 9.77
- 52 Week Low
- GKOS $77.91
- BKU $26.69
- 52 Week High
- GKOS $163.71
- BKU $44.45
- Technical
- Relative Strength Index (RSI)
- GKOS 41.74
- BKU 47.36
- Support Level
- GKOS $87.17
- BKU $30.29
- Resistance Level
- GKOS $94.55
- BKU $31.48
- Average True Range (ATR)
- GKOS 6.28
- BKU 1.71
- MACD
- GKOS 1.04
- BKU 0.20
- Stochastic Oscillator
- GKOS 52.17
- BKU 57.55
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.